Drug intelligence / Profile preview

PD-DP-008

Development stage: Phase 1
Lead developer: Chengdu Peide Biopharmaceutical
Modality: Small Molecules
Administration: Topical

Overview

PD-DP-008 is an investigational drug developed by Chengdu Peide Biopharmaceutical for the treatment of acne vulgaris. It is currently in early clinical development, with a Phase 1 trial evaluating its safety, tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy in healthy adult subjects and patients with mild to moderate acne vulgaris. The precise mechanism of action and molecular target have not been disclosed in public sources as of June 2025.

Beyond the preview

Go deeper on PD-DP-008.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PD-DP-008.